Cantor Fitzgerald Predicts BBIO FY2025 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($4.50) per share for the year. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share.

Other equities analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a research note on Monday, December 16th. Oppenheimer began coverage on BridgeBio Pharma in a report on Thursday, October 3rd. They set a “market perform” rating for the company. Evercore ISI raised their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Scotiabank upped their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, November 25th. Finally, Leerink Partners decreased their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.08.

BridgeBio Pharma Stock Down 0.3 %

BBIO stock opened at $35.73 on Thursday. The firm has a 50 day moving average of $28.27 and a 200 day moving average of $26.74. The stock has a market capitalization of $6.75 billion, a PE ratio of -14.80 and a beta of 1.05. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $41.04.

Insider Activity

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,156 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the transaction, the chief financial officer now owns 93,758 shares in the company, valued at $2,101,116.78. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares in the company, valued at $109,751,697.63. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.66% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its position in shares of BridgeBio Pharma by 17.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after buying an additional 801 shares in the last quarter. Amalgamated Bank grew its position in shares of BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after purchasing an additional 962 shares during the last quarter. Diversified Trust Co increased its stake in shares of BridgeBio Pharma by 3.0% during the 3rd quarter. Diversified Trust Co now owns 36,772 shares of the company’s stock worth $936,000 after purchasing an additional 1,059 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in BridgeBio Pharma by 21.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock valued at $170,000 after buying an additional 1,214 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of BridgeBio Pharma by 27.1% in the second quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $190,000 after acquiring an additional 1,600 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.